eBC and mBC Treatment | KISQALI (ribociclib)
WEBLearn about HR+, HER2- metastatic breast cancer treatment in premenopausal and postmenopausal women with KISQALI. See full Prescribing & Safety Info.
Kisqali: What to Expect, Side Effects, and More - Breastcancer.org
WEBKisqali (ribociclib) is a CDK4/6 inhibitor used to treat certain cases of estrogen-receptor-positive, HER2-negative breast cancer.
FDA approves Kisqali and Kisqali Femara Co-Pack
WEB4 days ago · On September 17, 2024, the FDA approved ribociclib (Kisqali, Novartis Pharmaceuticals Corporation) with an aromatase inhibitor and ribociclib and letrozole co-pack (Kisqali Femara Co-Pack,...
KISQALI® (ribociclib) for HR+, HER2- Metastatic Breast Cancer
WEBLearn about HR+, HER2- metastatic breast cancer treatment in premenopausal and postmenopausal women with KISQALI. See full Prescribing & Safety Info.
Breast cancer treatment: Drug Kisqali approval expanded for …
WEB4 days ago · In a phase 3 clinical trial from the drugmaker Novartis, Kisqali reduced the risk of a patient’s breast cancer coming back by 25% after three years when given in addition to standard treatments,...
How Kisqali Works for Breast Cancer - WebMD
WEBKisqali (ribociclib) is a medicine used for certain types of breast cancer. Kisqali is used to treat breast cancer that is hormone receptor (HR)-positive and human epidermal growth factor...
Kisqali Plus Hormone Therapy for Metastatic Breast Cancer
WEBJan 11, 2023 · The combination of ribociclib with a drug to block hormones (endocrine therapy) has recently become a standard treatment for postmenopausal women with hormone receptor – positive, HER2-negative metastatic …
Kisqali: Uses, Dosage, Side Effects, Warnings - Drugs.com
WEBSep 25, 2023 · Kisqali is used to treat hormone-related breast cancer in women. Ribociclib is used only if your cancer tests negative for a protein called human epidermal growth factor receptor 2 (HER2). HER2 protein can speed the growth of cancer cells.
- [PDF]
kisqali - Novartis
WEBKISQALI is indicated for the treatment of adults with HR-positive, HER2-negative advanced or metastatic breast cancer in combination with: an aromatase inhibitor as initial endocrine-based therapy; or
Dosing & Administration | KISQALI® (ribociclib)
WEBKISQALI Is a Convenient Once-Daily Oral Tablet. KISQALI is taken by mouth on a 4-week dosing cycle in combination with either an oral nonsteroidal aromatase inhibitor (NSAI) (eg, letrozole or anastrozole) or fulvestrant, an injection administered by …
Skip to content